Literature DB >> 27424989

Expression of microRNA miR-34a inhibits leukemia stem cells and its metastasis.

S Wang1, T Wang, M-Z Li, X-L Cheng, X-L Li.   

Abstract

OBJECTIVE: To study the expression profile and role of microRNA miR-34a in Leukemia stem cells (LSC) and during its metastasis. We examined upon the enforced expression of miR-34a in TIM3 positive leukemia stem cells and study the impact of leukemia stem cells and its metastasis. PATIENTS AND METHODS: Samples were collected from acute myeloid leukemia (AML) children along with controls. Immunohistochemistry analysis was performed with TIM3 antibody followed by Sorting of TIM3 positive cells by flow cytometry and the expression level of miR-34a was quantified by qRT-PCR assay.
RESULTS: Immunohistochemistry in accordance with Sorting of TIM3 positive cells by flow cytometry concludes that the leukemia stem cells (LSC) were present in the samples. Induced expression of miR-34a in TIM3 positive leukemia stem cells (LSC), inhibits the clonogenic expansion, tumor progression and metastasis of leukemia.
CONCLUSIONS: The enforced expression of miR-34a in TIM3 positive leukemia stem cells inhibits the leukemia stem cells and its metastasis. Our study illustrates that miR-34a is a key regulator and which will be developed as a novel therapeutic agent against leukemia stem cells (LSC).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27424989

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

Review 1.  The biomarkers of leukemia stem cells in acute myeloid leukemia.

Authors:  Yahui Ding; Huier Gao; Quan Zhang
Journal:  Stem Cell Investig       Date:  2017-03-02

Review 2.  MicroRNAs Associated With a Good Prognosis of Acute Myeloid Leukemia and Their Effect on Macrophage Polarization.

Authors:  Alexandra Neaga; Cristina Bagacean; Adrian Tempescul; Laura Jimbu; Oana Mesaros; Cristina Blag; Ciprian Tomuleasa; Corina Bocsan; Mihaela Gaman; Mihnea Zdrenghea
Journal:  Front Immunol       Date:  2021-01-15       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.